UY27456A1 - Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados - Google Patents

Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Info

Publication number
UY27456A1
UY27456A1 UY27456A UY27456A UY27456A1 UY 27456 A1 UY27456 A1 UY 27456A1 UY 27456 A UY27456 A UY 27456A UY 27456 A UY27456 A UY 27456A UY 27456 A1 UY27456 A1 UY 27456A1
Authority
UY
Uruguay
Prior art keywords
derivatives
diabetes
treatment
related disorders
naftiridine
Prior art date
Application number
UY27456A
Other languages
English (en)
Inventor
Yamin Wang
William Bullock
Libing Chen
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY27456A1 publication Critical patent/UY27456A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere, en general a derivados de naftiridina de la fórmula, en la cual uno de U, X, Y y Z es nitrógeno y los otros son C-R, donde R es hidrógeno o un sustituyente. Mas especificamente, la invención se refiere a derivados de 1,6-naftiridina y a composiciones farmacéuticas que contienen dichos derivados. Los métodos de la invención comprenden la administración de un derivado de naftiridina de la invención para el tratamiento de la diabetes y trastornos relacionados.
UY27456A 2001-09-26 2002-09-26 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados UY27456A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32451101P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
UY27456A1 true UY27456A1 (es) 2003-04-30

Family

ID=23263913

Family Applications (2)

Application Number Title Priority Date Filing Date
UY27457A UY27457A1 (es) 2001-09-26 2002-09-26 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
UY27456A UY27456A1 (es) 2001-09-26 2002-09-26 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY27457A UY27457A1 (es) 2001-09-26 2002-09-26 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados

Country Status (24)

Country Link
US (5) US6900205B2 (es)
EP (2) EP1432710A1 (es)
JP (2) JP2005504808A (es)
KR (2) KR20040041178A (es)
CN (2) CN1578781A (es)
AR (2) AR037504A1 (es)
BR (2) BR0212864A (es)
CA (2) CA2463039A1 (es)
CO (2) CO5560611A2 (es)
EC (2) ECSP045084A (es)
GT (2) GT200200194A (es)
HN (1) HN2002000275A (es)
HR (2) HRP20040309A2 (es)
HU (2) HUP0402310A2 (es)
IL (2) IL160707A0 (es)
MA (2) MA27079A1 (es)
MX (2) MXPA04002136A (es)
NO (2) NO20041560L (es)
PE (2) PE20030601A1 (es)
PL (2) PL369567A1 (es)
RU (2) RU2004112787A (es)
UY (2) UY27457A1 (es)
WO (2) WO2003027112A1 (es)
ZA (2) ZA200403063B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212864A (pt) * 2001-09-26 2004-08-17 Bayer Pharmaceuticals Corp Derivados de 1,6-naftiridina como antidiabéticos
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
WO2005018567A2 (en) * 2003-08-22 2005-03-03 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
ATE452890T1 (de) * 2003-11-04 2010-01-15 Merck & Co Inc Substituierte naphthyridinonderivate
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP1771456A2 (fr) * 2004-07-30 2007-04-11 Palumed SA Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1916896A4 (en) * 2005-08-26 2010-08-11 Univ California NOT STEROID-antiandrogens
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
EP2150544B1 (en) * 2007-03-19 2016-01-13 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US10017827B2 (en) 2007-04-04 2018-07-10 Nidera S.A. Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2839395A1 (en) * 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
ES2623777T3 (es) 2013-03-13 2017-07-12 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de la inmunodeficiencia humana
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
ES2843522T3 (es) 2015-02-27 2021-07-19 Incyte Corp Sales del inhibidor de PI3K y procesos para su preparación
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
BR112018002681A2 (pt) 2015-08-10 2019-04-24 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US990774A (en) * 1910-03-15 1911-04-25 John W P Reid Convertible core for building-blocks.
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4616019A (en) 1984-01-26 1986-10-07 Abbott Laboratories Naphthyridine antibacterial compounds
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US5116840A (en) 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4810708A (en) 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
CA2001203C (en) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
CA2012681A1 (en) 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
JP3012684B2 (ja) * 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
KR950704314A (ko) 1992-12-01 1995-11-17 가와노 다케히코 1,8-나프티리딘-2-온 유도체 및 그 사용 방법(1,8-naphthyridin-2-one derivative and use thereof)
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
CZ292631B6 (cs) 1994-06-14 2003-11-12 Dainippon Pharmaceutical Co., Ltd. Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující
JP3242792B2 (ja) 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
CN1043993C (zh) 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
EP0841929B1 (en) 1995-08-02 2003-05-07 Darwin Discovery Limited Quinolones and their therapeutic use
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
ES2191183T3 (es) 1996-08-06 2003-09-01 Pfizer Derivados 6,6- o 6,7-biciclicos que contienen pirido o pirimido sustituidos.
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
HUP0001054A3 (en) 1997-08-06 2001-01-29 Daiichi Asubio Pharma Co Ltd 1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
CA2285352A1 (en) 1998-01-29 1999-08-05 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity
KR100286874B1 (ko) 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
WO2000016774A1 (fr) 1998-09-18 2000-03-30 Senju Pharmaceutical Co., Ltd. Procede de solubilisation de l'acide pyridonecarboxylique, solubilisant a cet effet, preparations de solutions aqueuses contenant de l'acide pyridonecarboxylique et leur procede de production
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
EP1276739A2 (en) 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
BR0212864A (pt) * 2001-09-26 2004-08-17 Bayer Pharmaceuticals Corp Derivados de 1,6-naftiridina como antidiabéticos

Also Published As

Publication number Publication date
US20060189609A1 (en) 2006-08-24
JP2005504807A (ja) 2005-02-17
CN1578781A (zh) 2005-02-09
US20040157875A1 (en) 2004-08-12
GT200200194A (es) 2003-07-03
ECSP045084A (es) 2004-06-28
HUP0402310A2 (hu) 2005-02-28
WO2003027113A1 (en) 2003-04-03
PE20030601A1 (es) 2003-09-07
NO20041560L (no) 2004-05-11
ZA200403064B (en) 2005-06-29
ECSP045081A (es) 2004-06-28
KR20040041178A (ko) 2004-05-14
KR20040041177A (ko) 2004-05-14
WO2003027112A1 (en) 2003-04-03
US7109196B2 (en) 2006-09-19
AR037503A1 (es) 2004-11-17
RU2004112771A (ru) 2005-10-10
IL160708A0 (en) 2004-08-31
MXPA04002035A (es) 2004-06-07
BR0212829A (pt) 2004-08-03
ZA200403063B (en) 2005-04-22
IL160707A0 (en) 2004-08-31
HRP20040309A2 (en) 2006-05-31
BR0212864A (pt) 2004-08-17
CN1578780A (zh) 2005-02-09
CO5560611A2 (es) 2005-09-30
PL369531A1 (en) 2005-05-02
HUP0401889A2 (hu) 2005-01-28
CO5560542A2 (es) 2005-09-30
US20040209866A1 (en) 2004-10-21
RU2004112787A (ru) 2005-10-10
US6900205B2 (en) 2005-05-31
MA26344A1 (fr) 2004-10-01
MXPA04002136A (es) 2005-03-07
PL369567A1 (en) 2005-05-02
HRP20040317A2 (en) 2006-06-30
HN2002000275A (es) 2005-02-22
EP1432710A1 (en) 2004-06-30
EP1432711A1 (en) 2004-06-30
NO20041567L (no) 2004-05-11
MA27079A1 (fr) 2004-12-20
US20040014751A1 (en) 2004-01-22
PE20030549A1 (es) 2003-08-18
AR037504A1 (es) 2004-11-17
CA2461132A1 (en) 2003-04-03
US6677352B1 (en) 2004-01-13
JP2005504808A (ja) 2005-02-17
GT200200191A (es) 2003-05-23
US6964971B2 (en) 2005-11-15
UY27457A1 (es) 2003-04-30
CA2463039A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
UY27456A1 (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
UY28805A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso par tratar la diabetes y trastornos relacionados
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
MY137535A (en) New pyrrolidinium derivatives
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
UY28150A1 (es) Agentes terapeuticos
ATE301653T1 (de) Pyrazolopyridine
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
GB0201508D0 (en) Organic compounds
NO20055977L (no) Nye benzimidazolderivater
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
NO20054787L (no) Indenderivater som farmasotiske midler
ATE300541T1 (de) Pyrazolopyridinderivate
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
ATE274515T1 (de) Pyrazolopyridinderivate
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130226